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A B S T R A C T
Between January 1993 and December 2001, the
overall frequency of resistance to third-generation
cephalosporins in isolates of Enterobacteriaceae
from Charles Nicolle Hospital, Tunis, rose from
2.4% to 7.4%. Klebsiella pneumoniae was the most
prevalent species (56%), followed by Escherichia
coli (15%) and Proteus mirabilis (9%). A rate of
49% was observed among isolates from paediat-
ric patients in 1999, caused mostly by outbreaks in
the neonatal intensive care unit of K. pneumoniae
and P. mirabilis isolates that produced extended-
spectrum b-lactamases.
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Acquired resistance to third-generation cephalo-
sporins among different species of enterobacteria
has become a growing problem worldwide [1,2].
Such resistance is often associated with transfer-
able plasmid-encoded class A extended-spectrum
b-lactamases (ESBLs) [1,2]. ESBL-producing
organisms are resistant to all b-lactams except
cephamycins and carbapenems. Since 1988, resist-
ance to cephamycins and broad-spectrum
cephalosporins has also appeared in enterobacte-
ria following the transfer of chromosomal genes
for inducible AmpC-type b-lactamases on to plas-
mids [3]. Unlike that of class A ESBLs, the activity
of AmpC-type b-lactamases is not inhibited by
clavulanic acid [4,5]. In addition, organisms pro-
ducing these enzymes are often resistant to many
other classes of antibiotics, including aminoglyco-
sides, tetracyclines, chloramphenicol, trimetho-
prim–sulphonamides and fluoroquinolones [3,4].
The prevalence of acquired resistance to third-
generation cephalosporins varies from country to
country [1–3,5]. In Tunisia, the first ESBL-produ-
cing isolate (of Klebsiella pneumoniae) was reported
at Charles Nicolle Hospital in 1984 [6,7], and the
first plasmid-mediated AmpC-type b-lactamase
was identified in 1996 in an isolate of Proteus
mirabilis [8]. Subsequently, resistance to third-
generation cephalosporins was found in different
species of enterobacteria causing nosocomial out-
breaks, with serious problems resulting for anti-
microbial therapy [7,9]. To evaluate the extent of
this type of resistance at Charles Nicolle Hospital,
and to strengthen control measures, a surveillance
programme was carried out.
During the period January 1993 to December
2001, 22 691 isolates of enterobacteria were
obtained from hospitalised patients in different
wards of Charles Nicolle Hospital, a 1000-bed
teaching hospital. All isolates were identified
using the API 20E system (bioMe´rieux, Marcy
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l’Etoile, France). Antimicrobial susceptibilities
were determined by disk diffusion on Mueller–
Hinton agar, with quality control tests performed
weekly with reference strains (Escherichia coli
ATCC 25922, Pseudomonas aeruginosa ATCC
27853 and Enterococcus faecalis ATCC 29212) [10].
ESBLs were detected with a double-disk synergy
(DDS) test. For isolates that were DDS-negative,
but with reduced inhibition zone sizes for cefo-
taxime and ceftazidime, MICs of ticarcillin, cefo-
taxime, cefoxitin and ceftazidime (alone and
combined with clavulanic acid 2 mg ⁄L) were
determined by agar dilution. Isolates with a
phenotype suggestive of chromosomal AmpC-
type b-lactamase were not included.
In total, 1245 non-duplicate clinical isolates
showed acquired resistance to third-generation
cephalosporins, but remained susceptible to imi-
penem (100%) and, mostly (89.2%), to cefoxitin.
Between 1993 and 2001, the frequency of acquired
resistance to third-generation cephalosporins in
enterobacteria ranged from 2.4% in 1993 to 7.4%
in 2001. However, an overall frequency of 8.8%
was observed in 1999, with the frequency of
resistance in paediatric patients reaching 49%.
Isolates came from patients in different wards,
but mostly (26%) from paediatric patients. Over-
all, 58% were from urine samples and 13% from
blood cultures. K. pneumoniae was the most pre-
valent species (56%), followed by E. coli (15%)
and P. mirabilis (9%) (Table 1).
Most (88.2%) of the isolates produced an ESBL
that was detected easily by the DDS test, in that
synergism was observed between clavulanic acid
and a third-generation cephalosporin. However,
11.8% of isolates were negative in the DDS test,
with reduced susceptibility to third-generation
cephalosporins; some of these showed synergism
between cefoxitin and a third-generation cepha-
losporin. The MICs of cefotaxime and ceftazidime
were increased (4 to > 128 mg ⁄L) more than the
MICs of cefoxitin, and did not decrease when
combinations with clavulanic acid (2 mg ⁄L) were
used. Of these isolates, 60% were resistant to
cefoxitin, with MICs > 4 mg ⁄L (characteristic of
AmpC-type b-lactamases [3,5]), while 40% had
low cefoxitin MICs (0.5–4 mg ⁄L). This latter pro-
file was first found in P. mirabilis isolates, but then
spread to other species (E. coli and K. pneumoniae),
mainly in urology and paediatric patients. This
phenotype has been reported previously by Bau-
ernfeind et al. [11], and was associated with an
AmpC-type b-lactamase designated ACC-1 that
was not induced by cefoxitin. All of these resistant
isolates had associated resistance to aminoglyco-
sides (47.6–79.3%), quinolones (28.9–33.6%) and
trimethoprim–sulphamethoxazole (48.7%).
ESBLs were first reported in Germany in 1983,
but they have now been described worldwide
[1,2]. They were isolated initially from K. pneumo-
niae and spread rapidly to different species of
enterobacteria [1,2]. At Charles Nicolle Hospital
in Tunisia, the frequency of isolation of entero-
bacteria resistant to third-generation cephalospo-
rins is increasing, particularly in the paediatric
ward where the first strain was reported [6,7]. The
highest resistance rate in 1999 was associated, in
part, with outbreaks caused by ESBL-producing
K. pneumoniae in the neonatal intensive care unit,
and ESBL-producing K. pneumoniae and P. mira-
bilis in the paediatric ward. These sporadic no-
socomial outbreaks, related to the failure of basic
hygiene measures, coupled with the widespread
use of third-generation cephalosporins, have led
Table 1. Species of Enterobacteria-
ceae showing resistance to third-
generation cephalosporins
Species
DDS-positive
(ESBL-positive) DDS-negative Total
No. % No. % No. %
Klebsiella spp. 656 60 41 28 697 56
Escherichia coli 135 12.5 51 34 186 15
Proteus mirabilis 72 6.5 39 26.5 111 9
Salmonella spp. 5 0.5 2 1.5 7 0.5
Citrobacter diversus 37 3 2 1.5 39 3
Serratia spp. 38 3.5 0 0 38 3
Enterobacter spp. 96 8.5 0 0 96 8
Citrobacter freundii 15 1.5 0 0 15 1
Other Proteus and
Providencia spp.
43 4 13 8.5 56 4.5
Total 1097 88.2 148 11.8 1245 100
DDS, double-disk synergy; ESBL, extended-spectrum b-lactamase.
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to an endemic problem in the hospital, which has
resulted in a concurrent dissemination of genes,
plasmids and strains.
Although ESBLs were present in 88.2% of
resistant isolates, 11.8% of isolates had a pheno-
type characteristic of AmpC-type b-lactamases.
Plasmid-mediated AmpC-type b-lactamases have
been reported in isolates of K. pneumoniae, E. coli,
Salmonella spp., Citrobacter freundii, Enterobacter
aerogenes and P. mirabilis [4,5]. The first AmpC-
type b-lactamase to be identified in Tunis was in
1996 in a P. mirabilis isolate, and was characterised
as a CMY-4 enzyme that conferred resistance to
all cephalosporins, including cephamycins, and
was related to the chromosomal enzyme of C.
freundii [8]. Subsequently, such enzymes were
found in a variety of enterobacteria, particularly
E. coli and K. pneumoniae [5,8]. The rapid increase
in the number and variety of enzymes conferring
resistance to third-generation cephalosporins has
now became a serious problem with major thera-
peutic implications, which emphasises the neces-
sity of implementing infection control measures
and promoting the rational use of antibiotics.
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Data on BacT ⁄Alert blood cultures in a Greek
hospital from 1995 to 2002 were analysed retro-
spectively. There was a gradual increase in the
number of blood cultures (4981 in 1995 to 9054 in
2002), the true positive rate (14.4% to 16.5%) and
the number of bloodstream infections ⁄ 1000 hos-
pital admissions (22.1 to 30.7). The five most
common pathogens were Eschericia coli, Staphylo-
coccus aureus, coagulase-negative staphylococci,
enterococci and Klebsiella spp. The relative rates of
Gram-negative and Gram-positive isolates
inverted during the study period because of an
increasing frequency of coagulase-negative sta-
phylococci and enterococci.
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